Levin Capital Strategies’s Lipocine LPCN Stock Holding History

Levin Capital Strategies’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-608	Closed	-$89K	–	385
2015 Q2	$89K	Buy	+608	New	+$75.5K	﹤0.01%	371

Other funds holding LPCN

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Levin Capital Strategies's LPCN Position: Q3 2015 in Review

Levin Capital Strategies sold out of Lipocine (LPCN) in Q3 2015, closing a stake of 608 shares — an estimated $89K sold.

Levin Capital Strategies first reported a position in LPCN in Q2 2015 and held it in 1 quarter. The position peaked at $89K in Q2 2015. 45 funds tracked by Wall St. Rank hold LPCN as of Q3 2015.

Levin Capital Strategies reported no remaining Lipocine position as of Q3 2015 after selling out during the quarter.
Levin Capital Strategies sold 608 Lipocine shares in Q3 2015, an estimated $89K.
Levin Capital Strategies first reported a position in Lipocine in Q2 2015 and held it in 1 quarter.
Levin Capital Strategies's Lipocine position peaked at $89K in Q2 2015.
45 funds tracked by Wall St. Rank held Lipocine as of Q3 2015.

Based on Levin Capital Strategies's 13F filing for Q3 2015, filed 13 Nov 2015.